We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 220.00
Bid: 218.00
Ask: 219.50
Change: 0.00 (0.00%)
Spread: 1.50 (0.688%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 220.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Biomedica swings to profit on Covid-19 vaccine sales

Wed, 22nd Sep 2021 07:03

(Sharecast News) - Covid-19 vaccine producer Oxford Biomedica swung to a profit in the half year on the back of a surge in revenues through its partnership deal with AstraZeneca and announced that Serum Institute of India has agreed to invest £50m in the group in return for a 3.9% stake in the company.
The company on Wednesday said operating core earnings rose to £27.1m from a £0.4m loss. Revenue increased by 139% to £81.3 m. On a pre-tax basis profit for the six months to June 30 amounted to £19.2.m, compared to year-on-year losses of £6.1m.

Group operating earnings before interest, tax, depreciation and amortisation for the second half were expected to be higher year on year, but lower than the first six months as a result of an increase in operating expenditure levels, the company said.

"The exceptional financial results that we have reported reflect our strong progress across the business as we continue to demonstrate our world leading expertise in gene and cell therapy," said chief executive John Dawson.

"As we move from strength to strength, and with rapid growth in the cell and gene therapy market, we are in a great position to maximise on the opportunities ahead, both in lentiviral vectors as well as other viral vector types and look forward to the remainder of 2021 and beyond with considerable confidence."

Operating expenses fell 19% to £23.6 million, which the company pinned on a higher recovery of batch manufacturing costs, which was reflected in increased cost of goods.

Oxford Biomedica said it continued large-scale commercial manufacture of AstraZeneca's Covid vaccine from three manufacturing suites. The two companies in May committed to increase the number of batches in the second half of the year 2021 - leading to Oxford lifting forecasts of cumulative revenues from the contract to be in excess of £100m by the end of the year.

In a separate statement, Oxford Serum Institute of India had agreed to invest just over £50m in the group in return for a 3.9% stake in the company.

Proceeds of the deal will be used to fund the development of the fallow area at Oxbox, the group's manufacturing facility based in Oxford "into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023", Oxford Biomedica said.
More News
22 Apr 2024 14:45

UK earnings, trading statements calendar - next 7 days

Tuesday 23 April 
Alphawave IP Group PLCFull Year Results
Anglo American PLCTrading Statement
ASA International Group PLCFull Year Results
Associated British Foods PLCHalf Year Results
Eleco PLCFull Year Results
GB Group PLCTrading Statement
Jupiter Fund Management PLCTrading Statement
Property Franchise Group PLCFull Year Results
Taylor Wimpey PLCTrading Statement
tinyBuild IncFull Year Results
Trellus Health PLCFull Year Results
Wednesday 24 April 
1Spatial PLCFull Year Results
abrdn PLCTrading Statement
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
Lloyds Banking Group PLCQ1 Results
Nichols PLCTrading Statement
PensionBee Group PLCFirst Quarter Results
PZ Cussons PLCTrading Statement
Quilter PLCQ1 Results
Reckitt Benckiser Group PLCTrading Statement
Sanderson Design Group PLCFull Year Results
Serica Energy PLCFull Year Results
Star Energy Group PLCFull Year Results
Tortilla Mexican Grill PLCFull Year Results
Tracsis PLCHalf Year Results
Warpaint London PLCFull Year Results
Thursday 25 April 
Aquila European Renewables PLCFull Year Results
Argo Blockchain PLCFull Year Results
AstraZeneca PLCQ1 Results
Barclays PLCQ1 Results
Checkit PLCFull Year Results
Coca-Cola Europacific Partners PLCTrading Statement
Destiny Pharma PLCFull Year Results
Dillistone Group PLCFull Year Results
Focusrite PLCHalf Year Results
Gem Diamonds LtdTrading Statement
Hikma Pharmaceuticals PLCTrading Statement
Hummingbird Resources PLCTrading Statement
Ibstock PLCTrading Statement
Inchcape PLCTrading Statement
J Sainsbury PLCFull Year Results
London Stock Exchange Group PLCQ1 Results
Persimmon PLCTrading Statement
Pinewood Technologies Group PLCFull Year Results
PPHE Hotel Group LtdTrading Statement
PureTech Health PLCFull Year Results
Relx PLCTrading Statement
Renewi PLCTrading Statement
Schroders PLCQ1 Results
Skillcast Group PLCFull Year Results
Travis Perkins PLCTrading Statement
Trifast PLCTrading Statement
Unilever PLCQ1 Results
WAG Payment Solutions PLCTrading Statement
Weir Group PLCTrading Statement
WH Smith PLCHalf Year Results
WPP PLCTrading Statement
Zinc Media Group PLCFull Year Results
Friday 26 April 
Facilities by ADF PLCFull Year Results
Kingspan Group PLCTrading Statement
NatWest Group PLC Q1 Results
Pearson PLCTrading Statement
Record PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Taylor Maritime Investments LtdTrading Statement
Monday 29 April 
Beazley PLCTrading Statement
Biome Technologies PLCFull Year Results
Christie Group PLCFull Year Results
Gresham Technologies PLCFull Year Results
Jadestone Energy PLCFull Year Results
Oxford BioMedica PLCFull Year Results
SpaceandPeople PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Apr 2024 09:43

LONDON BROKER RATINGS: HSBC likes Haleon, cuts Flutter to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
20 Mar 2024 16:18

EARNINGS AND TRADING: Roadside Real Estate trims Cambridge Sleep stake

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
5 Mar 2024 17:09

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Mar 2024 16:22

Oxford Biomedica shares rise on post-acquisition guidance

(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.

Read more
5 Mar 2024 08:57

LONDON BROKER RATINGS: Barclays cuts Bank of Ireland to 'equal weight'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
5 Feb 2024 11:34

EnSilica hires new chief financial officer from Oxford Biomedica

(Alliance News) - EnSilica PLC on Monday said it has appointed a new chief financial officer, who will join the company and board in May.

Read more
29 Jan 2024 12:35

IN BRIEF: Institut Merieux ups stake in Oxford BioMedica toward 10%

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell therapy - Completes purchase of ABL Europe SAS from Institut Merieux SA, cementing the partnership between Oxford BioMedica and Institut Merieux. ABL is a cell and gene therapy contract development and manufacturing organization with facilities in Lyon and Strasbourg in France. For the EUR15 million acquisition, Oxford BioMedica will issue 3.1 million new shares to Lyon-based Institut Merieux at a price of 407.4 pence, well above its current market price. This is a 3.2% stake, and Institut Merieux already had 3.3%, giving it a total 6.5% holding. Oxford BioMedica says Institut Merieux intends to raise this to 10.0% by the end of the September.

Read more
7 Dec 2023 21:10

Oxford BioMedica posts optimistic outlook on uptick in contract value

(Alliance News) - Oxford BioMedica PLC on Thursday said it is on track to achieve its guidance for the year, amid an uptick in current contracted value and growth supported by new orders.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
4 Dec 2023 10:32

Oxford BioMedica buys ABL Europe for consideration of EUR15 million

(Alliance News) - Oxford BioMedica PLC on Monday said that it has entered a sale and purchase agreement with TSGH SAS for the acquisition of ABL Europe SAS.

Read more
20 Oct 2023 10:02

SMALL-CAP WINNERS & LOSERS: Record down as managed assets decline

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Friday.

Read more
18 Oct 2023 09:39

LONDON BROKER RATINGS: Citigroup cuts Wizz Air to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
27 Sep 2023 11:24

Director dealings: TUI, Oxford Biomedica board members linked to buys

(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.

Read more
22 Sep 2023 09:33

LONDON BROKER RATINGS: BoA likes Dowlais; JPMorgan cuts Phoenix Group

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.